Lianhuan Pharmaceutical announced that Changle Pharmaceutical, a holding subsidiary of the company, has received the “Drug Registration Certificate” for mesartan potassium tablets approved and issued by the State Drug Administration. The drug is used to treat essential hypertension in adults. Changle Pharmaceutical invested about RMB 10.99 million in research and development of measartan potassium tablets. As of the announcement disclosure date, Changle Pharmaceutical has obtained 10 production approvals. Obtaining the “Drug Registration Certificate” this time is not expected to have a significant impact on the company's recent business performance.

Lianhuan Pharmaceutical announced that Changle Pharmaceutical, a holding subsidiary of the company, has received the “Drug Registration Certificate” for mesartan potassium tablets approved and issued by the State Drug Administration. The drug is used to treat essential hypertension in adults. Changle Pharmaceutical invested about RMB 10.99 million in research and development of measartan potassium tablets. As of the announcement disclosure date, Changle Pharmaceutical has obtained 10 production approvals. Obtaining the “Drug Registration Certificate” this time is not expected to have a significant impact on the company's recent business performance.